All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Allo-HSCT for elderly patients with MF: Results from the German Registry for Stem Cell Transplantation study
Bookmark this article
|
For patients with intermediate- or high-risk MF, allo-HSCT is typically recommended in patients aged <70 years.1 In recent years, an increased number of patients with MF aged ≥70 years have undergone allo-HSCT; however, data supporting allo-HSCT in these patients are limited.1 A multicenter, retrospective study using the DRST assessed the feasibility of allo-HSCT in 115 patients aged ≥70 years with MF.1 Results from this analysis were published in Transplantation and Cellular Therapy by Gagelmann et al.1 |
| Key learnings |
| The absolute number of allo-HSCT per year increased during 2007 to 2021, with a spike from 2019 onward. The HCT-CI of patients improved over time, and the proportion of patients receiving RIC increased. |
| Results suggest that allo-HSCT in patients aged ≥70 years with MF is feasible, with a 3-year OS rate of 55%. |
| The 1-year and 3-year CIR were 7% and 11%, respectively, and the 1-year and 3-year cumulative incidence of NRM were 22% and 38%, respectively. |
| The 100-day cumulative incidence of aGvHD and the cumulative incidence of cGvHD were 33% and 55%, respectively, and the 3-year estimated GRFS rate was 37%. Abbreviations: AE, adverse event; BAT, best available therapy; GI, gastrointestinal; MF, myelofibrosis; SVR35, spleen volume reduction. |
| Patients with unmutated CALR/MPL driver mutation genotype had lower survival compared with patients with CALR/MPL-mutated genotype (HR, 3.42; 95% CI, 1.01–11.60). HCT-CI and dose intensity did not impact survival. |
| This large, multicenter study demonstrated the survival benefit of allo-HSCT in patients aged ≥70 years with MF and highlights an increase in allo-HSCT rates and patient fitness in recent years. |
Abbreviations: aGvHD, acute graft-versus-host disease; allo-HSCT, allogeneic hematopoietic stem cell transplantation; cGvHD, chronic graft-versus-host disease; CI, confidence interval; CIR, cumulative incidence of relapse; DRST, German Registry for Stem Cell Transplantation; GRFS, graft-versus-host disease and relapse-free survival; HCT-CI, Hematopoietic Cell Transplantation-specific Comorbidity Index; HR, hazard ratio; MF, myelofibrosis; NRM, non-relapse mortality; OS, overall survival; RIC, reduced-intensity conditioning.
- Gagelmann N, Schuh C, Zeiser R, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: A study from the German Registry for Stem Cell Transplantation. Transplant Cell Ther. 2024;30(10):1011.e1-1011.e13. DOI: 1016/j.jtct.2024.07.026
More about...
Your opinion matters
19 votes - 79 days left ...
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox